| dc.contributor.author | LYNCH, MARINA ANNETTA | |
| dc.date.accessioned | 2013-08-07T11:03:15Z | |
| dc.date.available | 2013-08-07T11:03:15Z | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012 | en |
| dc.identifier.citation | O'Reilly JA, Lynch M, Rosiglitazone improves spatial memory and decreases insoluble A?(1-42) in APP/PS1 mice., Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7, 1, 2012, 140-4 | en |
| dc.identifier.other | Y | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | Identifying potential novel treatments for patients with Alzheimer?s disease (AD) is a major challenge and drugs used for other indications, particularly if they have anti-
inflammatory properties, are particularly attractive. The
nuclear receptor peroxisome proliferator-activated receptor-! (PPAR!) is a ligand-activated transcription factor. | en |
| dc.description.sponsorship | The Health Research Board, Ireland | en |
| dc.format.extent | 140-4 | en |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology; | |
| dc.relation.ispartofseries | 7; | |
| dc.relation.ispartofseries | 1; | |
| dc.rights | Y | en |
| dc.subject | Alzheimer?s disease | en |
| dc.subject.lcsh | Alzheimer?s disease | en |
| dc.title | Rosiglitazone improves spatial memory and decreases insoluble A?(1-42) in APP/PS1 mice. | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/lynchma | |
| dc.identifier.rssinternalid | 83609 | |
| dc.identifier.uri | http://hdl.handle.net/2262/66884 | |
